Metabolically Optimized Cell Culture
Patent No. EP3351620 (titled "Metabolically Optimized Cell Culture") was filed by Regeneron Pharmaceuticals on Oct 10, 2014. The application was issued on Sep 2, 2020.
Patent Summary
Production of proteins and/or polypeptides in cell culture that metabolically shift to lactate consumption. The production is achieved by culturing cells comprising a nucleic acid sequence encoding a protein of interest in a first cell culture and determining a metabolic shift to lactate consumption has occurred in said first cell culture.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3351620
- Application Number
- EP18161278A
- Filing Date
- Oct 10, 2014
- Status
- Revoked
- Apr 22, 2022
- Publication Date
- Sep 2, 2020
- External Links
- Slate, Register , Google Patents